


a. classification of subject matter IPC 7 C12N15/12 C07K14/47 C1201/68 C07K16/18 G01N33/68 A61K38/00 According to International Patent Classification (IPC) or to both national classification and IPC B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) C12N C07K IPC 7 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, CHEM ABS Data, EMBASE, BIOSIS, Sequence Search, WPI Data C. DOCUMENTS CONSIDERED TO BE RELEVANT Relevant to claim No. Citation of document, with indication, where appropriate, of the relevant passages Category ° 21,22, DATABASE GENESEQ wo0166689 X 18 December 2001 (2001-12-18), 24-29, TANG YT: "Novel human secretory 31-34. PΙ 45-47 protein, Seq ID No 336." XP002292983 54-75 retrieved from EBI Database accession no. AAU28167 the whole document DATABASE GENESEQ WO200272770 21,22, χ 24 - 2916 December 2002 (2002-12-16), SPYTEK KA,: "Human NOVX6b protein" 31-34. 45-47, XP002292984 54-75 retrieved from EBI Database accession no. ABG97484 abstract Patent family members are listed in annex. Further documents are listed in the continuation of box C. X Special categories of cited documents: *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the "A" document defining the general state of the art which is not considered to be of particular relevance invention ·E· earlier document but published on or after the international "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such docu-ments, such combination being obvious to a person skilled document referring to an oral disclosure, use, exhibition or other means in the art. document published prior to the international filing date but later than the priority date claimed *&* document member of the same patent family Date of mailing of the international search report Date of the actual completion of the international search 07/09/2004 27 August 2004 Authorized officer Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,

Fax: (+31-70) 340-3016

Gurdjian, D



C.(Continua	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	Relevant to claim No.
Category °	Citation of document, with Indication, where appropriate, of the relevant passages	Helevant to claim No.
X	DATABASE EMBL 1 October 2002 (2002-10-01), JIKUYA,H.: "FLJ00364 protein (Fragment)." XP002292985 retrieved from EBI Database accession no. Q8NF38 the whole document	21,22, 24-29, 31-34, 45-47, 54-75
x	DATABASE GENESEQ 20 January 2003 (2003-01-20), TANG YT: "Human polypeptide SEQ ID NO 1291" XP002292986 retrieved from EBI Database accession no. ABP69244 abstract	21,22, 24-29, 31-34, 45-47, 54-75
Α	JOHNSTON H ET AL: "Identification of a novel SNF2/SWI2 protein family member, SRCAP, which interacts with CREB-Binding Protein" JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 274, no. 23, 4 June 1999 (1999-06-04), pages 16370-16376, XP002148210 ISSN: 0021-9258	21,22, 24-29, 31-34, 45-47, 54-75
Α	WO 98/03652 A (US HEALTH; HOWARD BRUCE H (US); NAKATANI YOSHIHIRO (US)) 29 January 1998 (1998-01-29)	21,22, 24-29, 31-34, 45-47, 54-75
P,X	IOURGENKO VADIM ET AL: "Identification of a family of cAMP response element-binding protein coactivators by genome-scale functional analysis in mammalian cells." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 14 OCT 2003, vol. 100, no. 21, 14 October 2003 (2003-10-14), pages 12147-12152, XP002292982 ISSN: 0027-8424 the whole document	21,22, 24-29, 31-34, 45-47, 54-75
	·	

mational application No. PCT/EP2004/003182

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)				
This Inte	ernational Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:			
1. X	Claims Nos.: 1-20, 23, 30, 35-44, 49-53 because they relate to subject matter not required to be searched by this Authority, namely:			
	Although claims 1-20,49-53 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.			
2. X	Claims Nos.: 1-20, 23, 30, 35-44, 49-53 because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful international Search can be carried out, specifically:			
	see FURTHER INFORMATION sheet PCT/ISA/210			
з. [Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).			
Box II	Observations where unity of invention is lacking (Continuation of item 3 of first sheet)			
This in	ternational Searching Authority found multiple inventions in this international application, as follows:			
1.	As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.			
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.			
3.	As only some of the required additional search fees were timely paid by the applicant, this International Search Report			
_	covers only those claims for which fees were paid, specifically claims Nos.:			
ļ				
4.	No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:			
Rema	ark on Protest The additional search fees were accompanied by the applicant's protest.			
	No protest accompanied the payment of additional search fees.			

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box II.1

Although claims 1-20, 49-53 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box II.2

Claims Nos.: 1-20, 23, 30, 35-44, 49-53

Present claims 1-20, 23, 30, 35-44, 49-53 relate to pharmaceutical compositions and method of treatment or screening defined by reference to a desirable characteristic or property, namely identified modulators of CREAP. The claims cover all pharmaceutical compositions and method of treatment or screening having this characteristic or property, whereas the application provides no support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for pharmaceutical compositions and method of treatment or screening comprising identified modulators. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT).

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.

Interactional Application No PCT/EP2004/003182

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9803652 A	29-01-1998	AU 4043897 A WO 9803652 A2	10-02-1998 29-01-1998